Telehealth Firm Indicted on Alleged $100 Million Adderall Scheme

Done Global Inc. was federally indicted after prosecutors allege the telemedicine company ran a scheme to illegally distribute over $100 million in Adderall and other ADHD stimulants, conspiring to prescribe roughly 40 million pills to patients without medical need. Founder/CEO Ruthia He and clinical president David Brody were convicted in November, and DOJ says Done operated a subscription model that pressured prescribers to issue unnecessary prescriptions; settlement talks with the department reportedly failed before the indictment. The action signals heightened enforcement risk for digital health firms and could raise regulatory, legal and reputational pressure across the telehealth sector.

Analysis

Market structure: The indictment lifts regulatory risk premium on pure-play telehealth prescription models and narrows investor appetite for businesses monetizing repeat controlled-substance scripts. Winners in a tightening regime are large diversified PBMs/retailers (CVS, WBA) and compliance vendors that capture incremental dispensing volume or documentation fees; losers are high-multiple, growth telehealth names (TDOC, AMWL, GDRX) that rely on easy prescribing to sustain ARPU. Expect 5–15% re-rating of small-cap telehealth multiples over 3–12 months if enforcement broadens.

Risk assessment: Tail risks include cascading DOJ indictments of 1–4 additional telehealth platforms within 6–12 months or DEA rule changes that restrict remote prescribing of Schedule II stimulants—each could cut addressable market for ADHD telemedicine by 30–60%. Near-term (days–weeks) look for IV spikes and widened credit spreads for leveraged telehealth borrowers; medium-term (1–6 months) litigation and civil suits could produce multi-hundred-million dollar reserves; long-term (12–36 months) structural demand may shift to hybrid in-person models.

Trade implications: Favor defensive rotation into CVS (CVS) and WBA (WBA) while reducing/shorting isolated telehealth equities (TDOC, AMWL) and US-listed digital pharmacy aggregators (GDRX if applicable). Use defined-risk option structures: 3–9 month put spreads on TDOC sized to 1–2% portfolio downside and 9–12 month call spreads on CVS sized to 2–3% to capture regulatory-driven flow. Pair trades (long CVS, short TDOC) hedge macro while expressing regulatory dispersion.

Contrarian angles: The market may over-penalize telehealth bundling models where only a minority of platforms engaged in criminal schemes; high-quality telehealth operators with robust KOL-backed clinical governance and no controlled-substance revenue could be underowned—look for names with <10% revenue from stimulants. Historical parallels: opioid litigation re-priced parts of pharma for years but left best-governed firms intact; selective re-entry after 6–12 months post-regulatory clarity can capture 20–40% rebounds.

Key Decisions for Investors

• Establish a 1.5% portfolio short position in Teladoc (TDOC) via a 3–6 month put spread (buy ATM put, sell ~10–15% lower strike) to limit cash exposure; add if TDOC guidance is cut >5% or DOJ/DEA issues industry guidance within 90 days.
• Establish a 2–3% long position in CVS Health (CVS) via outright shares or a 9–12 month call spread (buy 0–15% OTM call, sell 30–40% OTM call) to capture 3–6% expected outperformance over 6–12 months as dispensing shifts to retail PBMs.
• Implement a pair trade: long CVS (2%) / short TDOC (1.5%) to express regulatory rotation while limiting beta; rebalance if relative performance diverges >5% or if DOJ indicts 2+ additional firms within 120 days.
• Allocate 1% to a compliance/clinical documentation play (VEEV) via 12-month calls or shares, targeting 5–10% upside if regulatory tightening drives enterprise software spend; re-evaluate after DEA/DOJ announcements in next 30–60 days.